<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:hpo ids='HP_0011010'>Chronic</z:hpo> <z:e sem="disease" ids="C0019693" disease_type="Disease or Syndrome" abbrv="">HIV infection</z:e> leads to increased risk of non-Hodgkin B-cell <z:hpo ids='HP_0002665'>lymphoma</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>However, only few recent data are available about their current management and prognosis in HIV-infected children since the advent highly active antiretroviral therapy (HAART) </plain></SENT>
<SENT sid="2" pm="."><plain>This multicenter retrospective study describes the 12 cases of B-cell non-Hodgkin <z:hpo ids='HP_0002665'>lymphoma</z:hpo> diagnosed in HIV-infected children in France between 1996 and 2009 </plain></SENT>
<SENT sid="3" pm="."><plain><z:hpo ids='HP_0000001'>All</z:hpo> children had moderate to severe immunosuppression and high <z:mp ids='MP_0001799'>viral</z:mp> load at the time of diagnosis </plain></SENT>
<SENT sid="4" pm="."><plain>Nine children had extracerebral primary sites and 3 had a primary central <z:mp ids='MP_0008912'>nervous</z:mp> system <z:hpo ids='HP_0002665'>lymphoma</z:hpo> </plain></SENT>
<SENT sid="5" pm="."><plain>Eight patients had Burkitt <z:hpo ids='HP_0002665'>lymphoma</z:hpo>; 4 had diffuse large B-cell <z:hpo ids='HP_0002665'>lymphoma</z:hpo> </plain></SENT>
<SENT sid="6" pm="."><plain>Concomitantly with HAART, <z:hpo ids='HP_0000001'>all</z:hpo> children with extracerebral <z:hpo ids='HP_0002665'>lymphoma</z:hpo> received intensive chemotherapy according to LMB protocol, those with primary central <z:mp ids='MP_0008912'>nervous</z:mp> system <z:hpo ids='HP_0002665'>lymphoma</z:hpo> received high-dose <z:chebi fb="0" ids="44185">methotrexate</z:chebi> </plain></SENT>
<SENT sid="7" pm="."><plain>No toxicity-related <z:hpo ids='HP_0011420'>deaths</z:hpo> occurred </plain></SENT>
<SENT sid="8" pm="."><plain>Ten patients entered complete remission (CR), 2 died of <z:e sem="disease" ids="C0178874" disease_type="Neoplastic Process" abbrv="">tumor progression</z:e> despite a second line of therapy </plain></SENT>
<SENT sid="9" pm="."><plain>No relapses occurred after CR (median follow-up, 72 mo) </plain></SENT>
<SENT sid="10" pm="."><plain>Thus, prognosis of patients unresponsive to first-line <z:hpo ids='HP_0002665'>lymphoma</z:hpo> treatment remains poor, but relapse seems to be rare when CR is achieved </plain></SENT>
<SENT sid="11" pm="."><plain>Children without severe comorbidities can tolerate intensive chemotherapy with a mandatory HAART treatment, taking into account drug interactions </plain></SENT>
</text></document>